Join the Melanoma - Metastatic group to help and get support from people like you.
Melanoma - Metastatic News (Page 2)
UN Report Warns That Working in the Sun Causes Skin Cancers
THURSDAY, Nov. 9, 2023 (Healthday News) – New data from two United Nations agencies shows that millions of workers toiling under the sun's glare is fueling skin cancer cases around the world. Nearly...
AI Getting Better at Detecting Skin Cancer
FRIDAY, Nov. 3, 2023 – Artificial intelligence (AI) is increasingly accurate in detecting skin cancer, according to a study presented at the annual meeting of the European Academy of Dermatology and...
Latest AI Has 100% Success Rate in Spotting Melanomas
FRIDAY, Oct. 13, 2023 – The ability to detect skin cancer using artificial intelligence (AI) software has rapidly improved. New research presented Wednesday at a medical conference in Berlin shows...
Former 'Real Housewife' Teddi Mellencamp Reveals Another Melanoma Diagnosis
THURSDAY, Sept. 14, 2023 – Reality TV star and wellness coach Teddi Mellencamp announced on Instagram Wednesday that she has been diagnosed with yet another melanoma. This is Mellencamp’s 12th or 1...
In Situ, Invasive Melanoma Diagnoses Decreased in 2020
THURSDAY, Sept. 7, 2023 – During 2020, there were decreases seen for in situ and invasive melanoma diagnoses, according to a research letter published online Sept. 6 in JAMA Dermatology. Daniel Y....
Nivolumab + Ipilimumab Tops Ipilimumab Alone in Metastatic Melanoma
WEDNESDAY, Aug. 23, 2023 – For patients with metastatic melanoma who receive frontline anti-programmed death protein 1 (PD-1) or therapy against programmed cell death 1 ligand 1 and whose tumors...
Melanoma Presentation, Mortality Varies by Race
MONDAY, July 24, 2023 – Patterns of melanoma presentation, disease severity, and mortality vary by race, according to a research letter published online July 11 in the Journal of the American...
FDA Approves Opdualag (nivolumab and relatlimab-rmbw) for the Treatment of Patients with Unresectable or Metastatic Melanoma
PRINCETON, N.J.--(BUSINESS WIRE)-- March 18, 2022 – Bristol Myers Squibb (NYSE: BMY) today announced that Opdualag (nivolumab and relatlimab-rmbw),anew, first-in-class,fixed-dose combination of...
FDA Approves Keytruda (pembrolizumab) for the Adjuvant Treatment of Patients with Melanoma with Involvement of Lymph Node(s) Following Complete Resection
KENILWORTH, N.J.--(BUSINESS WIRE) February 19, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Mektovi (binimetinib) and Braftovi (encorafenib) in Combination for Unresectable or Metastatic Melanoma with BRAF Mutations
On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib (Braftovi and Mektovi, Array BioPharma Inc.) in combination for patients with unresectable or metastatic...
Array BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresectable or Metastatic Melanoma with BRAF Mutations
BOULDER, Colo., June 27, 2018 /PRNewswire/ – Array BioPharma Inc. (Nasdaq: ARRY) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi capsules in combination with...
Bristol-Myers Squibb’s Opdivo (nivolumab) Now the First and Only FDA-Approved PD-1 Inhibitor to Offer Every Four-Week Dosing
PRINCETON, N.J.--(BUSINESS WIRE) March 6, 2018 --Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License...
Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease
PRINCETON, N.J.--(BUSINESS WIRE)-- December 20, 2017 Bristol-Myers Squibb Company (NYSE:BMY) announced today that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection...
FDA Expands Approval of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
PRINCETON, N.J.--(BUSINESS WIRE) July 24, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy...
Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or Metastatic Melanoma Across BRAF Status
PRINCETON, N.J., January 23, 2016 --(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) in...
Ask a question
To post your own question to this support group, sign in or create an account.